---
document_datetime: 2025-11-27 09:37:26
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/celdoxome-pegylated-liposomal-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: celdoxome-pegylated-liposomal-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.3876391
conversion_datetime: 2025-12-27 21:34:34.347939
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

| Application number   | Scope                                                               | Opinion/ Notification 1 issued on product   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                |
|----------------------|---------------------------------------------------------------------|---------------------------------------------|---------------------------------------------|----------------------------------|------------------------------------------------------------------------------------------------------------------------|
| T/0004               | Transfer of Marketing Authorisation                                 | 19/02/2024                                  | 21/03/2024                                  | SmPC, Labelling and PL           |                                                                                                                        |
| PSUSA/1172/ 202211   | Periodic Safety Update EU Single assessment - doxorubicin Medicinal | 22/06/2023                                  | 23/08/2023                                  | SmPC and PL                      | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for |

Celdoxome pegylated liposomal Procedural steps taken and scientific information after the authorisation Medicinal product no longer authorised

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<div style=\"page-break-after: always\"></div>

|           |                                                                                                                                                          |            |            |                        | PSUSA/1172/202211.   |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|----------------------|
| IA/0003   | B.II.b.5.c - Change to in-process tests or limits applied during the manufacture of the finished product - Deletion of a non-significant in-process test | 08/08/2023 | n/a        |                        | authorised           |
| IAIN/0002 | A.1 - Administrative change - Change in the name and/or address of the MAH                                                                               | 13/04/2023 | 23/08/2023 | SmPC, Labelling and PL |                      |

<!-- image -->